The Canadian Institutes of Health Research (CIHR) recently approved the research proposals of seven IRCM researchers with the total sum of $11,433,708.
“Once again, the IRCM researchers’ success rate stood out from the national average,” said the IRCM’s President and Scientific Director, Tarik Möröy. “These results reflect the high-quality research that is being accomplished at the institute.”
IRCM researchers obtained a success rate of 26%, once again surpassing the national average, which is 13% for this competition (both rates include bridge funding).
Foundation Scheme
The CIHR approved grant applications of three researchers within the Foundation Grant competition, which is designed to contribute to a sustainable establishment of new, mid-career, and senior investigators that are leaders in their fields by providing long-term financial support for the pursuit of innovative, high-impact research programs.
- Tarik Möröy, Director of the Hematopoiesis and Cancer research unit, is granted $3,345,430 over seven years for his project Transcriptional control of hematopoiesis, immune cell differentiation and leukemia.
- Rémi Rabasa-Lhoret, Director of the Metabolic Diseases research unit, is granted $1,058,015 over seven years for his project Using artificial pancreas closed-loop systems for the treatment of type 1 diabetes.
- Nabil G. Seidah, Director of the Biochemical Neuroendocrinology research unit, is granted $3,761,408 over seven years for his project The proprotein convertases and their partners in health and disease.
Project Scheme
Five grants were approved within the Project Grant competition.
- Michel Cayouette, Director of the Cellular Neurobiology research unit, is granted $818,015 over five years for his project Molecular mechanisms regulating temporal identity in neural progenitors. He also obtained a five-year grant of $990,030 for his project entitled Temporal identity factors in retinal progenitors: opening new avenues for cell therapy in retinal degenerations.
- Éric A. Cohen, Director of the Human Retrovirology research unit, is granted $710,985 over five years for his project Targeting of host antiviral and immune-modulatory factors by HIV-1 Vpu: Implications for viral pathogenesis and therapy.
- Jennifer Estall, Director of the Molecular Mechanisms of Diabetes research unit, is granted $649,825 over five years for her project PGC-1a co-activators in beta-cell function and survival.
- François Robert, Director of the Chromatin and Genomic Expression research unit, receives a one-year bridge funding of $100,000 for his project Investigating the role of H2A.Z-mediated cryptic transcription in cancers.
About the IRCM
Founded in 1967, the Institut de recherches cliniques de Montréal (IRCM) is a non-profit organization that conducts fundamental and clinical biomedical research in addition to training high-level young scientists. With its cutting-edge technology facilities, the institute brings together 34 research teams, which work in cancer, immunology, neuroscience, cardiovascular and metabolic diseases, systems biology and medicinal chemistry. The IRCM also operates a research clinic specialized in hypertension, cholesterol, diabetes and cystic fibrosis, as well as a research centre on rare and genetic diseases in adults. The IRCM is affiliated with the Université de Montréal and associated with McGill University. Its clinic is affiliated with the Centre hospitalier de l’Université de Montréal (CHUM). The IRCM is supported by the Ministère de l’Économie, de la Science et de l’Innovation (Quebec ministry of Economy, Science and Innovation).
Source:
Anne-Marie Beauregard, Communications Officer, IRCM
514 987-5555 | anne-marie.beauregard@ircm.qc.ca
